Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$852.0m

Sana Biotechnology Future Growth

Future criteria checks 0/6

Sana Biotechnology's earnings are forecast to decline at 3.8% per annum while its annual revenue is expected to grow at 83.6% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -75.4% in 3 years.

Key information

-3.8%

Earnings growth rate

6.1%

EPS growth rate

Biotechs earnings growth28.4%
Revenue growth rate83.6%
Future return on equity-75.4%
Analyst coverage

Low

Last updated04 Sep 2024

Recent future growth updates

Recent updates

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology: Exciting Preclinical Science

Feb 12

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Oct 13
Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Sana Biotechnology: Hypoimmune Cell Therapies

Jul 01

Sana Biotechnology reports Q1 results

May 05

Earnings and Revenue Growth Forecasts

NasdaqGS:SANA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-334-267-1884
12/31/2025N/A-289-244-1834
12/31/2024N/A-277-168-1994
6/30/2024N/A-245-285-240N/A
3/31/2024N/A-309-274-240N/A
12/31/2023N/A-283-274-254N/A
9/30/2023N/A-276-288-278N/A
6/30/2023N/A-362-292-279N/A
3/31/2023N/A-320-307-292N/A
12/31/2022N/A-269-311-290N/A
9/30/2022N/A-300-346-324N/A
6/30/2022N/A-298-335-310N/A
3/31/2022N/A-207-310-279N/A
12/31/2021N/A-356-281-251N/A
9/30/2021N/A-358-212-179N/A
6/30/2021N/A-327-198-166N/A
3/31/2021N/A-433-183-158N/A
12/31/2020N/A-285-162-138N/A
9/30/2020N/A-215-155-134N/A
12/31/2019N/A-131-112-86N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SANA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SANA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SANA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SANA is forecast to have no revenue next year.

High Growth Revenue: SANA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SANA is forecast to be unprofitable in 3 years.


Discover growth companies